Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(−2) twice daily, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Batista, N, Perez-Manga, G, Constenla, M, Ruiz, A, Carabantes, F, Castellanos, J, Gonzalez Barón, M, Villman, K, Söderberg, M, Ahlgren, J, Casinello, J, Regueiro, P, Murias, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410278/
https://www.ncbi.nlm.nih.gov/pubmed/15150624
http://dx.doi.org/10.1038/sj.bjc.6601784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410278/
https://www.ncbi.nlm.nih.gov/pubmed/15150624
http://dx.doi.org/10.1038/sj.bjc.6601784

Ejemplares similares